Revised SPC: Symkevi (ivacaftor, tezacaftor) 100mg/150mg film coated tablets

The SPC now advises ivacaftor/tezacaftor has been studied with pitavastatin, an OATP1B1 substrate, and was found to have no clinically relevant effect on the exposure of pitavastatin. Therefore no dose adjustment of OATP1B1 substrates is required when co-administered with Symkevi


electronic Medicines compendium